ema semaglutide naion june 2025 Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 2-5 Non-Arteritic Anterior Ischemic Optic Neuropathy

First-generation incumbents, such as Wegovy or Zepbound, may benefit from a first-mover advantage building on a large body of evidence, HCPs extensive hands-on experience and possibly brand loyalty, especially from patients in out-of-pocket market segments

Stephens, A

"Growth hormone-releasing peptides and their analogues." Frontiers in Neuroendocrinology, 19(1), 4772

Sustaining weight loss after tirzepatide discontinuation requires comprehensive lifestyle modification and, in some cases, alternative pharmacotherapy

They might also improve insulin signaling in your brains gray matter, protecting the brain cells you use for thinking, says Michal Schnaider Beeri, Ph.D., director of the Herbert and Jacqueline Krieger Klein Alzheimers Research Center at Rutgers University

Year one in the first year that it's on the market, Victoza does roughly 300 million in sales